Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DPR-VAX

Financiado

Dipeptide Repeat Vaccine to prevent ALS and FTD in C9orf72 mutation carriers

Neurodegenerative diseases are triggered by protein aggregation in the CNS, but developing therapies has been challenging. Since key disease mechanisms change during disease progression, halting further neuron loss has not been ac... ver más

31/05/2022

BUNDESMINISTERIUM...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

BUNDESMINISTERIUM FUER GESUNDHEIT No se ha especificado una descripción o un objeto social para esta compañía.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-05-31

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

BUNDESMINISTERIUM FUER GESUN...

150.00K€ | Lider

EDASA INGENIERIA Y MONTAJES

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

C9-T Immunity Do T cells link loss and gain-of-function mechanism in C9orf... 1M€ Cerrado

FJC2021-046836-I Studying the central role of TDP-43 in ALS and other TDP-43... 65K€ Cerrado

PID2019-109276RA-I00 BASES ESTRUCTURALES DE LA TOXICIDAD DE ENSAMBLADOS TEMPRANOS... 157K€ Cerrado

PDC2022-133268-I00 GAMMA-PEPTIDOS BASADOS EN CIS-4-AMINO L-PROLINA COMO TERAPIA... 144K€ Cerrado

GA-VAX Advancing a vaccine targeting genetic amyotrophic lateral sc... 2M€ Cerrado

CORFEDITING Gene Editing as Therapeutic Strategy for C9ORF72 Linked ALS... 150K€ Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2019-12-10
Fecha Fin: 2022-05-31

Líder del proyecto

BUNDESMINISTERIUM FUER GESUNDHEIT No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 150K€

Descripción del proyecto Neurodegenerative diseases are triggered by protein aggregation in the CNS, but developing therapies has been challenging. Since key disease mechanisms change during disease progression, halting further neuron loss has not been achieved and may not even improve the symptoms and survival. Causal therapy is most realistic for monogenic disease variants. About 10% of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases are caused by repeat expansion in the C9orf72 gene. We have shown that the expanded repeat is translated into multiple aggregating dipeptide repeat (DPR) proteins. Poly-GA, the most abundant DPR species, is a key driver of downstream pathology. A poly-GA vaccine reduces aggregates and almost completely prevents motor deficits in our mouse model. With additional validation and safety experiment we will generate a pharma-ready data package for rapid preclinical and clinical devel-opment of the vaccine as first-in-class drug for prevention of ALS and FTD in C9orf72 carriers. The parallel development of suitable biomarkers to show clearance of DPR aggregates in vivo will greatly accelerate clinical trials. Thus, we will optimize our published immunoassays to allow more sensitive detection of DPRs in patient CSF. Moreover, we will develop our patented DPR monoclonal antibodies into a PET tracer. The solid data package is complemented by internal and external expertise in business development and regulatory affairs to shape an attractive business proposition and create value. ERC-PoC funding will allow us to present the opportunity to potential partners in large pharmaceutical companies and reputable venture capitalists for licensing or spin-off generation. Another proven strategy in the rare disease space would be collaboration with patient organizations to fund initial clinical trials. Preventing fatal ALS and FTD using vaccination in C9orf72 mutation carriers would be cost-effective for society and a blessing for affected families.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores